• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract Oral poly(ADP-ribose) polymerase inhibitors were associated with an increased risk of myelodysplastic syndrome and acute myeloid leukaemia over placebo treatment in patients with cancer

byKathleen Lau
January 22, 2021
in StudyGraphics
0
Share on FacebookShare on Twitter

RELATED REPORTS

Extended aromatase inhibitor therapy reduces breast cancer recurrence in postmenopausal women

Schrödinger Halts CDC7 Inhibitor After Two Patient Deaths

Talazoparib and enzalutamide improve survival in metastatic castration-resistant prostate cancer

Tags: acute myeloid leukaemiaacute myeloid leukemiaacute myeloid leukemia (AML)AMLblood cancercancerexposurefirst exposurehematologic cancerhematologyleukemiamdsmeta-analysismyelodysplastic syndromeMyelodysplastic Syndromesoncologyparp inhibitorplacebosafetysafety meta-analysis
Previous Post

Increased close contact leads to spread of Andes virus in Argentina

Next Post

Oral azacytidine maintenance therapy improved survival outcomes in patients with acute myeloid leukemia

RelatedReports

Incidental findings common with breast imaging, often benign
Chronic Disease

Extended aromatase inhibitor therapy reduces breast cancer recurrence in postmenopausal women

August 21, 2025
Improved survival with bufulfan-cyclophosphamide combination vs total body irradiation
Pharma

Schrödinger Halts CDC7 Inhibitor After Two Patient Deaths

August 20, 2025
Radiation plus hormone therapy may improve prostate cancer survival
Chronic Disease

Talazoparib and enzalutamide improve survival in metastatic castration-resistant prostate cancer

August 14, 2025
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Pharma

2 Minute Medicine: Pharma Roundup – Landmark lung approval, billion-dollar obesity drug deal, oncology safety halt, and GSK’s China push [August 14 2025]

August 14, 2025
Next Post
Quick Take: Factors associated with successful discontinuation of immune suppression after allogenic hematopoietic cell transplantation

Oral azacytidine maintenance therapy improved survival outcomes in patients with acute myeloid leukemia

Patient Basics: Parkinson’s Disease

Focused ultrasound subthalamotomy revealed improvement in Parkinson’s patients

Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs

Pembrolizumab linked to longer cancer-free period in advanced colon cancer

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Extended aromatase inhibitor therapy reduces breast cancer recurrence in postmenopausal women
  • GSK and Hengrui Pharma Forge $500 Million China Collaboration
  • #VisualAbstract: Ciprofloxacin is Noninferior to Aminoglycoside–Ciprofloxacin for Treatment of Bubonic Plague
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.